Full-Time

Medical Director

Autoantibody, Pipeline

Updated on 7/21/2026

Johnson & Johnson

Johnson & Johnson

10,001+ employees

Global healthcare company offering pharma, devices.

No salary listed

Horsham, PA, USA

Hybrid

Hybrid schedule: three days in the office, two days remote per week.

Category
Medical, Clinical & Veterinary (1)

Get referred to Johnson & Johnson

Find people who can refer or advise you

Requirements
  • MD, DO, PhD or PharmD degree is required
  • At least 8-10 years total healthcare related experience (academic clinical research, clinical practice, and/or pharmaceutical industry)
  • Experience in clinical trial design (Phase IIIb & IV) is required
  • This position is located in Horsham, PA and follows a hybrid schedule of three days in the office and two days remotely per week
  • Experience with clinical study, registry, or real-world evidence
Responsibilities
  • Work with the Autoantibody Therapeutic Area Lead, as well as other individuals within Medical Affairs and other functional areas within J&J, as necessary, to facilitate research and expanding the knowledge of J&J products for autoimmune diseases
  • Provide subject matter expertise and function as US medical representative with internal stakeholders across multiple functional areas including marketing and sales, health economics and outcomes research, MSLs, and medical information.
  • Develop and execute Medical Affairs sponsored/supported Phase IIIb/IV trials, registries, real-world evidence, and collaborations by leading study design, protocol development, analysis plan development, and providing overall trial leadership (including execution, monitoring, supervision, compliance, and risk identification/ mitigation).
  • Write as well as provide editorial comments for Phase IIIb/IV clinical study reports, abstracts and manuscripts related to J&J supported and sponsored studies.
  • Contribute to the preparation of regulatory submissions and interactions with Health Authorities (particularly the FDA) and help to ensure regulatory post-marketing commitments are efficiently satisfied with cost-effective, efficient, and scientifically rigorous methods.
  • Provide US medical input to Research & Development (R&D), including input into design of R&D clinical trials, presentations and publications.
  • Contribute to US Autoantibody Medical Affairs strategy, and potentially leads one or more integrated evidence teams (IETs) for approved and pipeline Autoantibody products/indications, working cross-functionally with partners within the Autoantibody IET, including Medical Science Liaison (MSL) team leaders, Real World Value & Evidence, Strategic Customer Group, Marketing brand teams, as well as potentially Autoantibody Disease Area Stronghold, R&D, Global Medical Affairs, MSL and Global Commercial partners to promote and execute the Autoantibody TA Strategy for establishing access plans for and progress and outcomes for evidence generation activities and dissemination plans.
  • Contribute to and potentially lead (as the Integrated Evidence Team Leader) the cross-functional team to develop and maintain a current, strategically aligned and annually updated Integrated Evidence Generation Plan (IEGP) for approved and pipeline products/indications. Support payer-related materials and data needs to scientifically support market access efforts.
  • Collaborate with external investigators and thought leaders; serve as a liaison between company and clinical investigators and thought leaders, and develop credible relationships with thought leaders, medical directors, key regulatory officials, medical societies and patient advocacy organizations.
  • Review and evaluate Investigator-Initiated Study concepts, champion prioritized concepts through appropriate review, approval, & funding, and monitor study progress/milestones.
  • Support/ lead the development of medical education content for field medical team. Partner with medical communications and scientific exchange teams on content development, review, and approval.
Desired Qualifications
  • Pharma industry experience is highly preferred
  • Medical Affairs experience is a strong asset
  • Experience interacting with health care professionals and other thought leaders is a strong asset
  • Evidence of strong scientific writing skills and analytical thinking is essential
  • Ability to work in a matrix environment is essential for success in this role
  • Up to 25% travel is required
  • Maternal Fetal Medicine, Medical Affairs, Strategic Thinking (from skills)
  • Autoimmune Diseases, Clinical Research, Collaboration, Cross-Functional Partnerships, Immunology, Launch Strategy, Maternal Fetal Medicine, Medical Affairs, Strategic Thinking

Johnson & Johnson operates in three main areas—pharmaceuticals, medical devices, and consumer health products—serving consumers, healthcare professionals, and institutions worldwide. It develops prescription medicines, sells surgical and vision care devices, and offers over-the-counter and personal care products, funded by direct sales, partnerships, and distribution agreements, with heavy investment in research and development. The company differentiates itself by combining three complementary businesses under one umbrella and maintaining a global footprint with an emphasis on science, innovation, and inclusive culture. Its goal is to help people live healthier lives by delivering reliable, high-quality healthcare products and solutions that improve patient outcomes.

Company Size

10,001+

Company Stage

IPO

Headquarters

New Brunswick, New Jersey

Founded

1886

Get referred to Johnson & Johnson

Find people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • J&J's stock surged 47.1% over the past year, outperforming the healthcare sector.
  • FDA approved J&J's Dual Energy cardiac ablation platform for electrophysiology in 2026.
  • J&J's 2026 revenue will exceed $100 billion for the first time in history.

What critics are saying

  • 58,206 pending talc ovarian cancer lawsuits risk multi-billion payouts within 12–24 months.
  • Eli Lilly's obesity drugs dominate 56% of its revenue, eroding J&J's pharma growth.
  • Abiomed's Impella trial failure forces J&J's cardiovascular unit to contract by 10–15%.

What makes Johnson & Johnson unique

  • J&J uniquely spans pharmaceuticals, MedTech, and consumer health across 140 years.
  • Its Dual Energy THERMOCOOL platform delivers both radiofrequency and pulsed field energy.
  • J&J raised 2026 revenue guidance to $100.8–$101.4 billion after Q2 beat.
  • J&J's oncology portfolio gained multiple FDA approvals in early 2026.
  • MedTech growth is fueled by Shockwave (2024) and Abiomed (2022) acquisitions.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Paid Sick Leave

Paid Holidays

Remote Work Options

Performance Bonus

Growth & Insights and Company News

Headcount

6 month growth

-3%

1 year growth

-3%

2 year growth

-1%
Johnson & Johnson
Jun 8th, 2026
Johnson & Johnson to Acquire Firefly Bio, Inc. to Expand Oncology Pipeline with Novel Degrader Antibody Conjugate Platform

• Expands the Company’s expertise in targeting pan-KRAS and other drivers of hard-to-treat cancers • Acquisition adds a proprietary degrader antibody conjugate platform designed to overcome key limitations of existing therapeutic approaches • Strengthens leadership in next-generation antibody engineering to accelerate oncology innovation

Yahoo Finance
Apr 14th, 2026
J&J's Spravato hits $468M in Q1 sales, signalling upside for psychedelics peers like Atai

Johnson & Johnson's Spravato reported $468 million in first-quarter 2026 sales, up 46% year over year, signalling potential for psychedelics-focused companies like AtaiBeckley Inc., according to Jefferies analysts. The esketamine nasal spray, approved for treatment-resistant depression, is on track to reach an annualised run rate exceeding $1.9 billion. Jefferies maintained that Spravato could hit $3 billion in annual sales by 2027 and $5 billion at peak. Over 200,000 patients have been treated globally, up from 140,000 at the start of 2025. Analysts said Spravato's commercial success demonstrates psychedelics can succeed in mainstream healthcare, with existing treatment infrastructure potentially easing adoption of emerging therapies. They highlighted ATAI's intranasal candidate BPL-003 as fitting seamlessly into Spravato's treatment paradigm.

Yahoo Finance
Apr 14th, 2026
J&J hits $100B milestone with 6.4% growth, eyes double-digit revenue by decade's end

Johnson & Johnson reported 6.4% operational sales growth in Q1 2026, raising full-year guidance to $100.2 billion — the first time the company has reached the $100 billion milestone. The company reaffirmed expectations for double-digit revenue growth by decade's end. Innovative Medicine grew 7.4%, driven by 10 double-digit growing brands including DARZALEX and TREMFYA, despite a 61.7% decline in STELARA due to biosimilar competition. MedTech posted 4.6% growth, led by heart recovery and electrophysiology divisions. The company successfully launched ICOTYDE, the first oral IL-23 peptide for immunology. Management is progressing a $55 billion US manufacturing and R&D investment through 2029, with $12 billion already deployed. The planned separation of its DePuy Synthes Orthopaedics business targets mid-2027 completion.

Business Wire
Apr 7th, 2026
Johnson & Johnson launches VARIPULSE Pro in Europe with 5x faster ablation for atrial fibrillation treatment

Johnson & Johnson has launched VARIPULSE Pro in Europe following CE Mark approval, advancing its pulsed field ablation portfolio for treating atrial fibrillation. The system features a new pulse sequence that operates five times faster than its predecessor whilst maintaining equivalent lesion quality. VARIPULSE Pro integrates with the CARTO 3 mapping system and offers a lower temperature profile whilst preserving the platform's established safety and effectiveness profiles. The company is conducting the VARIPURE multicentre study to generate clinical evidence during the commercial launch phase. The technology addresses atrial fibrillation, the most common cardiac arrhythmia affecting over 50 million people worldwide. Johnson & Johnson will showcase VARIPULSE Pro at the European Heart Rhythm Association annual meeting, with 12-month interim study results to be presented. The device is not currently approved in the United States.

Yahoo Finance
Apr 3rd, 2026
J&J's dividend stays resilient despite market sell-offs and healthcare challenges

Johnson & Johnson has raised $120 million in a Series C round led by Ribbit Capital, valuing the company at $1.45 billion. Sequoia and Kleiner Perkins participated, with Emerson Collective joining as a new backer. The pre-revenue company is developing "Mathematical Superintelligence", an AI system focused on advanced reasoning that claims to eliminate hallucinations by requiring outputs in Lean4 programming language. Its flagship model, Aristotle, achieved top-level performance at the International Mathematical Olympiad in July. Founded in 2023, Harmonic has raised $295 million across three funding rounds in 14 months. The company currently offers Aristotle via a free API and plans to commercialise in safety-critical industries like aerospace and finance.